LGALS1 and Insulin resistance: One of the first to indicate a role for galectin-1 in insulin resistance was a study of 10 obese but otherwise healthy insulin-resistant men treated with the insulin sensitizing PPAR-γ agonist rosiglitazone (4 mg bid) for 14 days [72].